Granulocyte colony-stimulating factor "mobilized" peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy.

Hematopoietic growth factors have been used to accelerate engraftment after bone marrow transplantation and to "mobilize" peripheral blood progenitor cells (PBPC). We report on the data in 85 consecutive patients with Hodgkin's disease who were treated in a single institution using different methods to obtain PB progenitor cells. Use of granulocyte colony-stimulating factor for mobilization resulted in a significantly accelerated time to recovery of granulocytes (10 days v 12 days, P < .01) when compared with "nonmobilized" PBPC recipients. Similarly, use of mobilized PBPC resulted in a significantly accelerated time to platelet engraftment (13 days v 30 days, P < .001) when compared with "nonmobilized" recipients. Moreover, there was a statistically significant difference in total costs in favor of the group receiving "mobilized" PBPC.

[1]  D. Metcalf,et al.  The growth of mouse bone marrow cells in vitro. , 1966, The Australian journal of experimental biology and medical science.

[2]  R G Sweet,et al.  Fluorescence Activated Cell Sorting , 2020, Definitions.

[3]  D. Weisenburger,et al.  Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. , 1988, Blood.

[4]  A. Pileri,et al.  Granulocyte-macrophage colony-stimulating factor to harvest circulating hemopoietic stem cells for autransplantation. , 1989 .

[5]  R. Hoffman,et al.  Effect of recombinant and purified hematopoietic growth factors on human megakaryocyte colony formation. , 1988, Experimental hematology.

[6]  L. Sachs,et al.  The cloning of normal "mast" cells in tissue culture. , 1965, Journal of cellular physiology.

[7]  A. Vannucchi,et al.  In vivo stimulation of megakaryocytopoiesis by recombinant murine granulocyte-macrophage colony-stimulating factor. , 1990, Blood.

[8]  M. LaQuaglia,et al.  Myeloablative combination chemotherapy without total body irradiation for neuroblastoma. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  G. Bonadonna,et al.  Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. , 1989, Blood.

[10]  J. Fay,et al.  Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation. , 1989, Blood.

[11]  N. Nicola,et al.  Proliferative effects of purified granulocyte colony‐stimulating factor (G‐CSF) on normal mouse hemopoietic cells , 1983, Journal of cellular physiology.

[12]  J. Armitage,et al.  High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. , 1987, The New England journal of medicine.

[13]  Peter M. Lansdorp,et al.  Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. , 1991, Blood.

[14]  R. Advani,et al.  Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as an Adjunct to Autologous Hemopoietic Stem Cell Transplantation for Lymphoma , 1992, Annals of Internal Medicine.

[15]  R. Andrews,et al.  Action of interleukin-3, G-CSF, and GM-CSF on highly enriched human hematopoietic progenitor cells: synergistic interaction of GM-CSF plus G-CSF. , 1989, Blood.

[16]  R. M. Fox,et al.  Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy , 1992, The Lancet.

[17]  O. Colvin,et al.  Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. , 1986, The New England journal of medicine.

[18]  C. Bennett,et al.  Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease. , 1992, Annals of internal medicine.

[19]  C. Begley,et al.  Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. , 1992, Lancet.

[20]  J. Armitage,et al.  Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. , 1991, The New England journal of medicine.

[21]  B. Sikic,et al.  Modulation of etoposide (VP-16) cytotoxicity by verapamil or cyclosporine in multidrug-resistant human leukemic cell lines and normal bone marrow. , 1990, Experimental hematology.

[22]  R. Bast,et al.  High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. Jagannath,et al.  Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Michael D. Green,et al.  GRANULOCYTE COLONY-STIMULATING FACTOR AND NEUTROPHIL RECOVERY AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE MARROW TRANSPLANTATION , 1989, The Lancet.

[25]  E. Thomas.  High-dose therapy and bone marrow transplantation. , 1985, Seminars in oncology.